Journal Home
Search for

Volume 28, Issue 3, Pages 249-255 (June 2009)


View previous. 7 of 26 View next.

Critically ill infants benefit from early administration of protein and energy-enriched formula: A randomized controlled trial

Dick A. van WaardenburgaCorresponding Author Informationemail address, Carlijn T. de Betuea, Johannes B. van Goudoeverb, Luc J. Zimmermanna, Koen F. Joostenb

Received 16 March 2008; accepted 15 March 2009.

Summary 

Background & aims

Nutritional support improves outcome in critically ill infants but is impeded by fluid restriction, gastric intolerance and feeding interruptions. Protein and energy-enriched infant formulas may help to achieve nutritional targets earlier during admission and promote anabolism.

Methods

Randomized controlled design. Infants with respiratory failure due to RSV-bronchiolitis received a protein and energy-enriched formula (PE-formula, n=8) or a standard formula (S-formula, n=10) during 5 days after admission. Primary outcome: nutrient delivery, energy and nitrogen balance and plasma amino acid concentrations. Secondary outcome: tolerance and safety.

Results

Nutrient intakes were higher in PE fed infants and met population reference intake (PRI) on day 3–5 whilst in S-fed infants PRI was met on day 5 only. Cumulative nitrogen balance (cNB) and energy balance (cEB) were higher in PE-infants compared to S-infants (cNB: 866±113 vs. 296±71mg/kg; cEB: 151±31 and 26±17kcal/kg, both P<0.01). Essential amino acid levels were higher in PE-infants but within reference limits whereas below these limits in S-infants. Both formulas were well tolerated.

Conclusions

Early administration of a protein and energy-enriched formula in critically ill infants is well tolerated, promotes a more adequate nutrient intake and improves energy and nitrogen balance without adverse effects.

a Department of Pediatrics, Maastricht University and Medical Center, P Debeyelaan 25, 6202 AZ Maastricht, The Netherlands

b Department of Pediatrics, Erasmus Medical Center/Sophia, Rotterdam, The Netherlands

Corresponding Author InformationCorresponding author. Tel.: +31 43 3875245; fax: +31 43 3875246.

 Clinical trial registration number: Nederlands trial register, Trial ID: NTR515, acronym: Infatrinistudie.

PII: S0261-5614(09)00067-3

doi:10.1016/j.clnu.2009.03.005


View previous. 7 of 26 View next.